Strategies to improve the reporting of legal blindness in Massachusetts

Autor: William H. Herman, Mona M. El-Hashimy, James H. Warram, Barbara A. Harrigan, Kate Alich, Ronald E. Aubert

Publikováno v: American journal of public health. 87(3)

OBJECTIVES: Registration practices were evaluated as the initial phase of a validation study of the Register of the Massachusetts Commission for the Blind. METHODS: Massachusetts eye care providers were surveyed to determine factors associated with n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42b86d51ff2ee7c2eb8599e5dd1cd770
https://pubmed.ncbi.nlm.nih.gov/9096546

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

Autor: Wen PY; Neuro-oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA patrick_wen@dfci.harvard.edu., Rodon JA; Medical Oncology, Hospital Vall d'Hebron, Barcelona, Catalunya, Spain., Mason W; Radiation-Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., Beck JT; Highlands Oncology Group, Fayetteville, Arkansas, USA., DeGroot J; Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Donnet V; Novartis Pharma SAS, Paris, France., Mills D; Novartis Pharma AG, Basel, Basel-Stadt, Switzerland., El-Hashimy M; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Rosenthal M; Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Publikováno v: ESMO open [ESMO Open] 2020 Jul; Vol. 5 (4).

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Autor: Campone M; Centre René Gauducheau, Institut de Cancérologie de L'Ouest, Saint Herblain, France. Electronic address: Mario.Campone@ico.unicancer.fr., Im SA; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Iwata H; Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan., Clemons M; Division of Medical Oncology, Ottawa Hospital Research Institute, Ottawa, Canada., Ito Y; Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Awada A; Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium., Chia S; Medical Oncology, BC Cancer Agency, Vancouver, Canada., Jagiełło-Gruszfeld A; Oncology Center, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, Poland., Pistilli B; Macerata Hospital, Macerata, Italy., Tseng LM; Department of Surgery, Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan., Hurvitz S; UCLA Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, USA., Masuda N; Department of Surgery and Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan., Cortés J; Institute of Oncology, Ramón y Cajal University Hospital, Madrid, Spain; Breast Cancer Research Program, Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain., De Laurentiis M; Breast Cancer Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy., Arteaga CL; Vanderbilt-Ingram Cancer Center, Department of Medicine, Vanderbilt University, Nashville, USA., Jiang Z; Department of Breast Cancer, Beijing 307 Hospital of PLA, Beijing, China., Jonat W; Medical Center, University Hospital Schleswig-Holstein, Kiel, Germany., Le Mouhaër S; Novartis Pharma S.A.S., Paris, France., Sankaran B; Novartis Institutes for BioMedical Research, Cambridge, USA., Bourdeau L; Novartis Pharma S.A.S., Paris, France., El-Hashimy M; Novartis Pharmaceuticals Corporation, East Hanover, USA., Sellami D; Novartis Pharmaceuticals Corporation, East Hanover, USA., Baselga J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2018 Nov; Vol. 103, pp. 147-154. Date of Electronic Publication: 2018 Sep 18.

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

Autor: Noguchi S; Department of Breast and Endocrine Surgery, Osaka University, Osaka, Japan, noguchi@onsurg.med.osaka-u.ac.jp., Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y

Publikováno v: Breast cancer (Tokyo, Japan) [Breast Cancer] 2014 Nov; Vol. 21 (6), pp. 703-14. Date of Electronic Publication: 2013 Feb 13.

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.

Autor: Hurvitz SA; Department of Medicine, Hematology/Oncology, UCLA Jonsson Comprehensive Cancer Center, 10945 Le Conte Avenue, PVUB Suite 3360, Los Angeles, CA, 90095, USA, shurvitz@mednet.ucla.edu., Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC, Gligorov J, Llombart A, Jhangiani H, Mirshahidi HR, Tan-Chiu E, Miao S, El-Hashimy M, Lincy J, Taran T, Soria JC, Sahmoud T, André F

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2013 Oct; Vol. 141 (3), pp. 437-46. Date of Electronic Publication: 2013 Oct 08.